Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
0s
·
ReachMD CME
·
CME credits: 0.50
Valid until: 14-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/safety-and-tolerability-of-changing-covalent-btk-inhibitor-treatment-in-a-patient-intolerant-to-ibrutinib-or-acalabrutinib/24454/
Selection of Bruton’s tyrosine kinase (BTK) inhibitor therapy in CLL patients requires recognizing key differences between first- and next-generation agents in terms of the safety profile and efficacy across all patient types, including patients with high-risk features. Newer BTK inhibitors with greater kinase selectivity have shown fewer off-target adverse effects and allowed patients to switch BTK inhibitors with continued clinical benefit, fewer recurrences, and lower severity.
The episode Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
from the podcast ReachMD CME has a duration of
0:00. It was first published
More episodes from ReachMD CME
Evolving Our View of the Coagulation Cascade and Stroke Management
CME credits: 0.25
Valid until: 30-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/evolving-our-view-of-the-coagulation-cascade-and-stroke-management/24144/
How can you improve long-term secondary stroke prevention in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA)? An understanding of how to apply emerging clinical trial data is critical, as is the evaluation of potential alternative agents that could expand the therapeutic options for these patients. In this activity, our expert faculty will add to your knowledge by reviewing the coagulation cascade and the relevance of inhibiting factors XI and XIa in stroke management.
=Consensus Recommendations for Use of p16/Ki67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
CME credits: 0.25
Valid until: 29-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consensus-recommendations-for-use-of-p16ki67-dual-staining-cytology-in-the-management-of-individuals-testing-positive-for-hpv/14675/
More effective triage tests are essential to improving cervical cancer risk-stratification and thus reducing the potential for unnecessary colposcopies. Enduring consensus cervical cancer screening recommendations, published in 2024, describe specific-use algorithms for p16/Ki-67 dual-staining cytology as an effective triage test, and also offer insight on how this test can best fit into clinical practice. Join Drs. Warner Huh and Kimberly Levinson as they first establish the rationale for using p16/Ki-67 dual-staining cytology and then break down the most salient algorithms for its use as offered in the recent recommendations.
=Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
CME credits: 0.25
Valid until: 22-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/strategic-excellence-mastering-the-expanding-attr-cm-therapeutic-landscape-in-pharmacy-practice/18124/
Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for more effective patient care. Don’t miss out on this opportunity to elevate the standard of care for your patients.
=Accurate Staging and Determining Resectability in NSCLC
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/accurate-staging-and-determining-resectability-in-nsclc/24385/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
CME credits: 1.00
Valid until: 15-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/consolidation-immunotherapy-after-concurrent-crt-what-do-real-world-data-show/24387/
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.